The market of rosuvastatin is treacherous. Who entered despite difficulties?

On April 26, the CDE website announced that Zhejiang Jiangbei Pharmaceutical Co., Ltd submitted the listing application of four new generic drugs of rosuvastatin calcium tablets, which made Jiangbei pharmaceutical become the sixth domestic enterprise applying for listing of rosuvastatin calcium tablets However, at the end of last year, Jingxin pharmaceutical won the bid in the "4 + 7" volume procurement and occupied the majority of market shares in 11 cities, so Jiangbei Pharmaceutical Co., Ltd Even if risuvastatin calcium tablet is successfully listed, it will inevitably compete with five other local enterprises besides Beijing New Pharmaceutical Co., Ltd According to the data of minenet, in 2017, the terminal sales of rosuvastatin calcium tablets, a public medical institution in China, reached 5.02 billion yuan Among them, AstraZeneca accounted for 56.71%, lunanbeite for 13.70%, Jingxin pharmaceutical for 13.37%, Zhengda Tianqing for 12.61%, Haizheng pharmaceutical for 1.98% and xianshengdongyuan for 1.63% In terms of specific sales data, Beijing New Pharmaceutical Co., Ltd sold over 500 million yuan in 2017, compared with over 300 million yuan in the first half of 2018; Zhengda Tianqing achieved 567 million yuan in 2017, about 320 million yuan in the first half of 2018; while Lunan Pharmaceutical Co., Ltd is currently the largest player in domestic generic drugs, exceeding 800 million yuan in 2018 It can be seen that AstraZeneca's original research drugs occupy a dominant position in China, but this kind of day did not last long In the "4 + 7" volume purchase bid winning price in December last year, Beijing new pharmaceutical's rosuvastatin calcium tablet of the same model won the bid in the corresponding region at a low price, with the price of 10mg * 28 tablets corresponding to 21.8 yuan It can be said that under the influence of volume purchase policy, Jiangbei pharmaceutical industry is targeting The competition environment of CDE's application for listing will be even worse Under the fog of layers, except for Beijing new pharmaceutical, other pharmaceutical companies are eyeing In addition, Jiangbei Pharmaceutical Co., Ltd., Zhejiang Jiangbei Pharmaceutical Co., Ltd., which submitted the application to CDE, is a non listed company By querying its official website, it can be found that the company has now formed seven categories of APIs, intermediates and solid preparations, including cardiovascular, central nervous, digestive, antiviral, anti infective, anticoagulant and anti osteoporosis Among them, there are 12 R & D pipelines including atorvastatin calcium tablets and rosuvastatin calcium tablets At present, simvastatin, atorvastatin, levetiracetam and other products have passed the official inspection and certification of FDA, CEP, who, Japan, South Korea, India and other products, and passed the new GMP inspection in China.